Details

Autor(en) / Beteiligte

• Park, Matthew D
• Reyes-Torres, Ivan
• LeBerichel, Jessica
• Hamon, Pauline
• LaMarche, Nelson M
• Hegde, Samarth
• Belabed, Meriem
• Troncoso, Leanna
• Grout, John A
• Magen, Assaf
• Humblin, Etienne
• Nair, Achuth
• Molgora, Martina
• Hou, Jinchao
• Newman, Jenna H
• Farkas, Adam M
• Leader, Andrew M
• Dawson, Travis
• D'Souza, Darwin
• Hamel, Steven
• Sanchez-Paulete, Alfonso Rodriguez
• Maier, Barbara
• Bhardwaj, Nina
• Martin, Jerome C
• Kamphorst, Alice O
• Kenigsberg, Ephraim
• Casanova-Acebes, Maria
• Horowitz, Amir
• Brown, Brian D
• De Andrade, Lucas Ferrari
• Colonna, Marco
• Marron, Thomas U
• Merad, Miriam

Titel

TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer

Ist Teil von

• Nature immunology, 2023-05, Vol.24 (5), p.792-801

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Natural killer (NK) cells are commonly reduced in human tumors, enabling many to evade surveillance. Here, we sought to identify cues that alter NK cell activity in tumors. We found that, in human lung cancer, the presence of NK cells inversely correlated with that of monocyte-derived macrophages (mo-macs). In a murine model of lung adenocarcinoma, we show that engulfment of tumor debris by mo-macs triggers a pro-tumorigenic program governed by triggering receptor expressed on myeloid cells 2 (TREM2). Genetic deletion of Trem2 rescued NK cell accumulation and enabled an NK cell-mediated regression of lung tumors. TREM2 mo-macs reduced NK cell activity by modulating interleukin (IL)-18/IL-18BP decoy interactions and IL-15 production. Notably, TREM2 blockade synergized with an NK cell-activating agent to further inhibit tumor growth. Altogether, our findings identify a new axis, in which TREM2 mo-macs suppress NK cell accumulation and cytolytic activity. Dual targeting of macrophages and NK cells represents a new strategy to boost antitumor immunity.